We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+55.74%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$531M
AUM Growth
+$61.3M
Cap. Flow
-$27.5M
Cap. Flow %
-5.17%
Top 10 Hldgs %
72.14%
Holding
37
New
3
Increased
6
Reduced
15
Closed
8

Top Buys

Rank Stock Value
1
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$11.3M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$10.3M
3
IMDZ
Immune Design Corp.
IMDZ
+$8.77M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$5.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$5.13M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$19.8M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$9.53M
3
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$8.21M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$8M
5
ARRY
Array Biopharma Inc
ARRY
+$6.96M

Sector Composition

Rank Sector Weight
1 Healthcare 77.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVLA
26
Palvella Therapeutics
PVLA
$2.15B
$1.86M 0.35%
12,707
+9,690
+321% +$1.29M
GYRE icon
27
Gyre Therapeutics
GYRE
$648M
$1.05M 0.2%
7,696
-935
-11% -$141K
GBIM
28
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
$822K 0.15%
657,653
– –
IONS icon
29
Ionis Pharmaceuticals
IONS
$8.85B
– –
-850,000
Closed -$19.8M
MGNX icon
30
MacroGenics
MGNX
$240M
– –
-200,000
Closed -$5.4M
SVRA icon
31
Savara
SVRA
$1.14B
– –
-52,814
Closed -$1.74M
VXRT
32
DELISTED
Vaxart
VXRT
– –
-18,941
Closed -$292K
PRTK
33
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-575,000
Closed -$8M
CALA
34
DELISTED
Calithera Biosciences, Inc
CALA
– –
-6,070
Closed -$450K
QLTI
35
DELISTED
QLT Inc
QLTI
– –
-2,255,476
Closed -$3.2M
VTAE
36
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-761,079
Closed -$8.21M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2016 Portfolio in Review

As of Q3 2016, BVF Inc held 37 positions worth $531M, up 13% from $469M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

BVF Inc withdrew a net $27.5M in Q3 2016, closing 8 positions and reducing 15 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 70% a quarter earlier.

Against the trend, BVF Inc opened a new position in CoLucid Pharmaceuticals, Inc. worth $29.1M.

  • BVF Inc's largest Q3 2016 buy was CoLucid Pharmaceuticals, Inc.: 763,300 shares worth $29.1M.
  • BVF Inc added most to Xenon Pharmaceuticals in Q3 2016, an estimated $10.3M increase.
  • BVF Inc's biggest Q3 2016 reduction was Tobira Therapeutics, Inc. Common Stock, cutting an estimated $9.53M.
  • BVF Inc fully exited Ionis Pharmaceuticals in Q3 2016, selling an estimated $19.8M.
  • BVF Inc's ten largest holdings make up 72% of its $531M portfolio in Q3 2016.
  • BVF Inc opened 3 new positions and closed 8 in Q3 2016.
  • BVF Inc's portfolio value rose 13% quarter-over-quarter to $531M.

Based on BVF Inc's 13F filing for Q3 2016, filed 14 Nov 2016.